According to the World Health Organisation, roughly half of all cancer deaths are due to late-stage diagnoses, highlighting the need for more effective early detection methods to best improve patient outcomes.
The solution
Elypta is a developing a new method for early cancer detection. Their approach involves analysing a substance called the GAGome in a urine or plasma sample and using machine learning to identify patterns that might indicate cancer.
Company achievements
210
Patients with rheumatic disease enrolled in a randomised control trial to improve wellbeing.